The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health officials seek newer information on vaccine results in the global fight against ...

The Food and Drug Administration said that 17 serious adverse events, including two that resulted in death, have been reported in worldwide recipients of the vaccine Ixchiq over the age of 60.

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes albopictus. It is a ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...

This update follows an earlier recommendation from the U.S. Advisory Committee on Immunization Practices (ACIP) to include a precaution related to the use of IXCHIQ® in persons aged 65 and over ...

The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into ...

17 serious adverse events, including two deaths, reported among adults 62–89 who received the Ixchiq vaccine. Ixchiq was approved in 2023 and has been distributed globally with 80,000 doses ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...

In November 2023, the FDA approved Ixchiq for the prevention of disease caused by the chikungunya virus in patients age 18 and older. Chikungunya is an infection caused by the chikungunya virus ...